GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ProKidney Corp.
Shares of ProKidney, a biotech company developing cell therapy for chronic kidney disease, reflect investors' faith in its revolutionary approach. The stock is highly volatile and driven by clinical trial news rather than current earnings.
Share prices of companies in the market segment - Pharma kidney
ProKidney is a biotech company developing innovative cell therapy for chronic kidney disease. We've categorized it in the "Pharma: Kidney" segment, and the chart below shows how investors view the prospects of companies working in this specific and important area of medicine.
Broad Market Index - GURU.Markets
ProKidney is a biotech company developing innovative cell therapy for chronic kidney disease. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance, reflecting investor expectations, with the overall market picture.
Change in the price of a company, segment, and market as a whole per day
PROK - Daily change in the company's share price ProKidney Corp.
Shares of ProKidney, a biopharmaceutical company specializing in kidney cell therapy, are extremely volatile. Change_co measures the market's reaction to clinical trial data. This metric is an essential component in building valuation models for companies at the forefront of regenerative medicine on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma kidney
ProKidney Corp. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with PROK, which focuses on kidney disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ProKidney is a biopharmaceutical company developing cell therapies for kidney disease. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing ProKidney's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ProKidney Corp.
ProKidney is a biopharmaceutical company specializing in the treatment of kidney diseases. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant component of the overall "noise" and stock market dynamics.
Annual dynamics of market capitalization of the market segment - Pharma kidney
ProKidney Corp. is a late-stage biotech developing cell therapy for chronic kidney disease. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its revolutionary approach and the high risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProKidney is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ProKidney Corp.
ProKidney, a biotech company developing cell therapy for chronic kidney disease, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its valuation. Successful trials can dramatically change the company's value.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
ProKidney Corp. is developing cell therapy for chronic kidney disease, at the forefront of regenerative medicine. This segment of biotechnology is attracting enormous attention but is fraught with high risks of clinical failure. The chart shows how much risk investors were willing to take on breakthrough, yet unproven, treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProKidney is a clinical-stage biotech company developing a therapy for kidney failure. Its shares are a venture capital investment in science. Their value is determined not by market trends, but by clinical trial results and regulatory decisions, creating an all-or-nothing binary outcome.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ProKidney Corp.
ProKidney is a biotech company developing cell therapy for kidney disease. Its weekly stock price is highly volatile, depending on news about clinical trials and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
ProKidney is a biotech company focused on cell therapy. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its innovative approach drives share price movements independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ProKidney, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A chart comparing it to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
PROK - Market capitalization of the company ProKidney Corp.
ProKidney's market capitalization is a bet on a revolutionary approach to treating chronic kidney disease using the patient's own cells. This biotech's stock price reflects the enormous investor hopes for its cell therapy. Its volatility reflects the market's reaction to trial data that could change the lives of millions of people.
PROK - Share of the company's market capitalization ProKidney Corp. within the market segment - Pharma kidney
ProKidney Corp. is a biotech company developing innovative cell therapies for chronic kidney disease (CKD) with the goal of restoring kidney function. Its market share reflects the enormous hopes for a breakthrough in this field. The chart below is a barometer of the market's belief in its potential to transform the lives of millions of patients.
Market capitalization of the market segment - Pharma kidney
ProKidney is developing cell therapy for chronic kidney disease, aiming to offer a regenerative solution. The chart below shows the overall market capitalization of the pharmaceutical sector. It illustrates the enormous scale of the kidney disease problem and the potential for companies that can offer breakthrough treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents hope for millions of patients with chronic kidney disease. ProKidney is developing a cell therapy that can restore kidney function. Its volatile line reflects the progress of clinical trials, visualizing a potential revolution in the treatment of one of the most common diseases.
Book value capitalization of the company, segment and market as a whole
PROK - Book value capitalization of the company ProKidney Corp.
ProKidney's capital consists of its intellectual property for a cell therapy for chronic kidney disease and financial reserves for its clinical development. This is scientific capital aimed at achieving breakthroughs in nephrology. The chart shows how the biotech company manages its research budget as it advances its innovative technology.
PROK - Share of the company's book capitalization ProKidney Corp. within the market segment - Pharma kidney
ProKidney is developing cell therapy for chronic kidney disease. Its uniqueness lies in its in-house manufacturing capabilities for creating this complex product. The chart shows the company's share of this cutting-edge and niche physical infrastructure for regenerative medicine.
Market segment balance sheet capitalization - Pharma kidney
Developing cell therapies for kidney disease, like ProKidney's, is a knowledge-intensive and potentially capital-intensive business. Given the pharmaceutical sector's assets, moving to the commercial stage will require the construction of expensive and complex manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
ProKidney's assets are not factories, but cutting-edge laboratories and a pilot plant for developing cell therapies aimed at restoring kidney function. The book value reflects the resources available for conducting innovative, yet experimental, research. The chart illustrates the scale of this biotech company within the sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ProKidney Corp.
ProKidney, which develops kidney cell therapy, has no revenue. Its market capitalization reflects investors' hope that its innovative technology will change the lives of millions of patients. Its ratio to its balance sheet (its cash flow) reflects the extent of this hope.
Market to book capitalization ratio in a market segment - Pharma kidney
ProKidney is a biotech company developing cell therapies for kidney disease. Its market valuation on this chart reflects investors' hope that its innovative approach will change treatment standards and capture a massive market.
Market to book capitalization ratio for the market as a whole
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Its goal is to restore kidney function and eliminate the need for dialysis. Its market valuation reflects a bet on a revolutionary approach to treating this common condition, illustrating the enormous premium placed on a potential medical breakthrough.
Debts of the company, segment and market as a whole
PROK - Company debts ProKidney Corp.
ProKidney, a clinical-stage biotech developing cell therapy for chronic kidney disease, is funding its expensive research and trials through a combination of equity and debt. This chart illustrates the costs of developing a breakthrough drug for a huge and unmet market.
Market segment debts - Pharma kidney
ProKidney is a late-stage biotech company developing cell therapy for chronic kidney disease. The goal is to restore kidney function and eliminate the need for dialysis. This chart shows how the company is funding its large-scale clinical trials, raising capital to bring this potentially revolutionary treatment to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ProKidney Corp.
ProKidney is a biotech company developing cell therapies for chronic kidney disease. Clinical trials in such a complex field are lengthy, expensive, and risky. This chart illustrates the company's reliance on debt to finance its innovative, but not yet commercially proven, developments.
Market segment debt to market segment book capitalization - Pharma kidney
ProKidney is a biotech company developing cell therapy for chronic kidney disease. It's an innovative but risky approach. This chart shows how the company is funding its expensive clinical trials. It compares its debt structure to the market capitalization of the entire capital-intensive biotech sector.
Debt to book value of all companies in the market
ProKidney Corp. is developing a cell therapy for chronic kidney disease. Biotech research is a marathon, requiring massive financial investments over many years. How dependent is the company on debt financing? This chart, showing the overall level of debt in the economy, provides context for assessing its financial survival strategy.
P/E of the company, segment and market as a whole
P/E - ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease. This chart reflects the high investor expectations for its innovative approach. Its highly volatile valuation depends on clinical trial results and market confidence in the company's ability to offer an alternative to dialysis and transplantation.
P/E of the market segment - Pharma kidney
ProKidney is a late-stage biotech company developing a first-of-its-kind cell therapy for chronic kidney disease. The goal is to restore kidney function. This chart shows the average valuation for the sector, giving investors context for evaluating this breakthrough, yet risky, technology.
P/E of the market as a whole
ProKidney is a biotech company developing cell therapy for chronic kidney disease. It's a breakthrough, but risky technology. Does the company's valuation exist in its own world of clinical data, or does the overall market sentiment reflected in this chart influence investor willingness to fund such long-term, capital-intensive projects?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease. The goal is to restore kidney function and eliminate dialysis. This chart reflects investors' confidence in the revolutionary potential of this technology. Future profits depend on the success of clinical trials and potential changes in treatment standards.
%20P%2FE%20ProKidney%20Corp.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ProKidney-Corp.&v=1772513647221 "Chart of the company's future (projected) P/E ProKidney Corp.")
Future (projected) P/E of the market segment - Pharma kidney
ProKidney is a biotech company developing cell therapy for chronic kidney disease, aiming to restore kidney function. This is a potentially revolutionary approach. The chart reflects expectations across the sector. This allows investors to compare their faith in ProKidney's breakthrough technology with the overall sentiment in the industry, where clinical trial failures are common.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772513647243 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
ProKidney Corp. is a biotech company developing cell therapy for chronic kidney disease. This is a revolutionary approach to treating this common condition. This market sentiment chart shows how willing investors are to fund breakthrough, yet early-stage, medical technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513647254 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Currently in clinical trials, it has no commercial revenue. The dynamics presented reflect the costs of cutting-edge research, which is an investment in a potentially revolutionary drug.
Profit of companies in the market segment - Pharma kidney
ProKidney is a biotech company developing cell therapy for chronic kidney disease. This chart, illustrating the financial health of the pharmaceutical sector, is important to them as an indicator of the investment climate. Positive dynamics in the industry help them attract funding for expensive clinical trials, which determine the future of their innovative treatment approach.
Overall market profit
ProKidney Corp. is developing a revolutionary therapy for chronic kidney disease using a patient's own cells. This is a cutting-edge, but expensive, area of medicine. The overall growth in corporate profits, visible in this chart, creates a favorable environment for attracting investment in such breakthrough biotech companies, accelerating the path from lab to patient.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease with the goal of restoring kidney function. The company's success depends on the results of clinical trials. This chart summarizes analyst opinions on the likelihood of approval of their revolutionary therapy and its future commercial potential.
%20profit%20of%20the%20company%20ProKidney%20Corp.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ProKidney-Corp.&v=1772513647328 "Graph of future (projected) profit of the company ProKidney Corp.")
Future (predicted) profit of companies in the market segment - Pharma kidney
ProKidney is a late-stage biotech company developing a cell therapy for chronic kidney disease. Its future depends entirely on regulatory approval and commercial launch. This chart, showing expectations for the biotech sector, reflects the overall investment climate and market confidence in the potential of breakthrough regenerative technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772513647350 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
ProKidney Corp. is developing a cell therapy for chronic kidney disease. The company's future depends on the success of clinical trials. However, the overall economic climate reflected in this forecast is impacting the ability of biotech companies to raise capital for expensive research and development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513647352 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ProKidney Corp.
ProKidney is a biotech company developing a groundbreaking cell therapy for chronic kidney disease. In the absence of revenue, this chart is key. It demonstrates the enormous value investors place on the potential future sales of its revolutionary treatment, betting on a medical breakthrough and a huge addressable market.
P/S market segment - Pharma kidney
ProKidney Corp. is developing a revolutionary cell therapy for chronic kidney disease, aiming to restore kidney function. The company's valuation is based on expectations for future sales of this potentially breakthrough treatment. This chart reflects the average valuation in the biotech sector, allowing investors to compare expectations for ProKidney's technology with overall sector trends.
P/S of the market as a whole
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Its goal is to offer a revolutionary treatment capable of restoring kidney function. This chart, which reflects revenue estimates for existing businesses, highlights the high level of investor hope for ProKidney's technology, which could change the treatment paradigm for millions of patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ProKidney Corp.
ProKidney is a biotech company developing cell therapy to treat chronic kidney disease, thereby avoiding dialysis and transplantation. Its valuation reflects hope for the future. This chart shows how investors view the potential of its revolutionary technology, which, if successful, could generate billions in future revenues.
%20P%2FS%20ProKidney%20Corp.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ProKidney-Corp.&v=1772513647388 "The graph of the company's future (projected) P/S ProKidney Corp.")
Future (projected) P/S of the market segment - Pharma kidney
ProKidney Corp. is a late-stage clinical development biotechnology company focused on developing cell therapies for chronic kidney disease. This chart reflects average revenue expectations for the biotech sector. It allows investors to assess how highly the market values ProKidney's potential to transform kidney treatment.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772513647390 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
ProKidney Corp. is developing a groundbreaking cell therapy for chronic kidney disease, aiming to restore kidney function. This graph reflects the market's overall revenue expectations. ProKidney's breakthrough could change the treatment paradigm for millions of patients and create a huge market, so its research is closely watched by investors anticipating a revolution in nephrology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513647394 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ProKidney Corp.
This chart shows the revenue of ProKidney Corp., a clinical-stage biotech focused on developing cell therapies for chronic kidney disease. Its revenue may currently be nonexistent or generated through partnerships, reflecting research progress rather than commercial sales of the finished product.
Sales of companies in the market segment - Pharma kidney
ProKidney Corp. is a late-stage biotech company developing a first-of-its-kind cell therapy for chronic kidney disease. This chart shows the potential market size for kidney disease treatments. If successful, ProKidney's technology could revolutionize treatment approaches and create a new multi-billion-dollar segment, saving patients' lives.
Overall market sales
ProKidney is a biotech company developing a treatment for chronic kidney disease. Its future depends on successful clinical trials and attracting investment. The overall economic situation, reflected in this chart, affects the availability of capital for funding innovative medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Future revenue depends on the success of clinical trials and regulatory approval. The chart reflects analyst expectations for the commercial potential of this revolutionary approach to medicine.
%20sales%20of%20the%20company%20ProKidney%20Corp.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ProKidney-Corp.&v=1772513647421 "Schedule of future (projected) sales of the company ProKidney Corp.")
Future (projected) sales of companies in the market segment - Pharma kidney
ProKidney is a biotech company developing a revolutionary cell therapy for chronic kidney disease, aiming to restore kidney function. The company's success could change the treatment paradigm for millions of patients. This graph shows the forecast for the entire pharmaceutical market, where kidney disease treatment represents a huge unmet need.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772513647424 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
ProKidney Corp. is developing a cell therapy for chronic kidney disease. The company's future depends on successful clinical trials and subsequent market acceptance. This chart illustrates the general investment landscape that influences biotech funding, but the key drivers for ProKidney are scientific data and regulatory decisions in the healthcare sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513647435 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ProKidney Corp.
ProKidney is a biotech company developing cell therapy for chronic kidney disease. While in clinical trials, it generates no revenue. This chart shows its net losses—the necessary investment in research and development to create a revolutionary product and change the paradigm of kidney disease treatment.
Market segment marginality - Pharma kidney
#VALUE!
Market marginality as a whole
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Their goal is to restore kidney function using a patient's own cells. Compared to this chart showing the state of the traditional economy, ProKidney represents an investment in a medical breakthrough. Their success depends on clinical data, not business cycles.
Employees in the company, segment and market as a whole
Number of employees in the company ProKidney Corp.
ProKidney is a biotech company developing cell therapies for chronic kidney disease. Its team is growing as it advances its complex product through late-stage clinical trials and establishes its own manufacturing facilities, a critical and labor-intensive process.
Share of the company's employees ProKidney Corp. within the market segment - Pharma kidney
ProKidney is developing a groundbreaking cell therapy for chronic kidney disease, aiming to prevent dialysis and transplantation. This chart shows the percentage of unique talent the company is attracting in its biotech niche. This growth indicates the company is expanding its scientific and clinical team to advance this potentially revolutionary technology.
Number of employees in the market segment - Pharma kidney
ProKidney Corp. is a late-stage clinical development biotech focused on treating chronic kidney disease with cell therapy. This chart reflects the employment dynamics in the cutting-edge field of regenerative medicine. The growing number of clinicians and scientists in this field suggests potential approval of a breakthrough treatment is approaching.
Number of employees in the market as a whole
ProKidney is a biotech company developing cell therapy for chronic kidney disease. Its innovative approach has the potential to dramatically change the lives of millions of patients. This milestone demonstrates how breakthroughs in regenerative medicine are creating new areas of healthcare and stimulating demand for highly qualified specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ProKidney Corp. (PROK)
ProKidney Corp. is a biotech company developing cell therapy for chronic kidney disease. This chart is a classic example of intellectual capital valuation. The company's value is based not on current revenue, but on the potential of its innovative therapeutic platform. The chart shows how highly the market values this future medical breakthrough per scientist and employee.
%20of%20the%20company%20ProKidney%20Corp.%20(PROK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ProKidney-Corp.-PROK&v=1772513647536 "Chart of market capitalization per employee (in thousands of dollars) of the company ProKidney Corp. (PROK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
ProKidney is a biotech company developing cell therapies for chronic kidney disease. Its valuation is based on the potential of its innovative platform. This chart reflects the high market valuation of its scientific developments based on its small team of scientists, which is typical for companies focused on developing breakthrough treatments.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772513647556 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
ProKidney is a biotech company developing cell therapy for chronic kidney disease. This chart reflects the valuation of its innovative approach to treating this common condition. The company's entire value is derived from its scientific potential. This indicator demonstrates the market's appreciation for the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513647561 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ProKidney Corp. (PROK)
ProKidney is a clinical-stage biotech company developing cell therapy for chronic kidney disease. This is cutting-edge, but very expensive, medicine. This chart reflects the cost of R&D. It shows how much capital the company burns per employee (scientist, physician) during complex clinical trials.
%20Chart%20ProKidney%20Corp.%20(PROK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ProKidney-Corp.-PROK&v=1772513647603 "Company Profit Per Employee (in thousands of dollars) Chart ProKidney Corp. (PROK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
ProKidney (PROK) is a biotech company developing a cell therapy (REACT) for the treatment of chronic kidney disease. It is a late-stage R&D company. This metric (loss per employee) reflects the enormous costs of conducting late-stage clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772513647604 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
ProKidney Corp. is a clinical-stage biotech company developing cell therapy (using a patient's own cells) for the treatment of chronic kidney disease. It's an R&D company. The company is not profitable. This chart shows the company's capital burn rate: the operating loss per research team developing this complex therapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513647612 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ProKidney Corp. (PROK)
ProKidney is a biotech company developing cell therapies for chronic kidney disease. This chart reflects the early stages of commercialization of its innovative platform. Any revenue at this stage is likely due to partnerships, and its growth per employee is a positive signal for investors.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ProKidney-Corp.-PROK&v=1772513647617 "Sales chart per company employee ProKidney Corp. (PROK)")
Sales per employee in the market segment - Pharma kidney
ProKidney is developing a revolutionary cell therapy for chronic kidney disease. In this cutting-edge biotech segment, this chart evaluates how efficiently the research team generates revenue (e.g., through partnerships) per employee. This is an indicator of the productivity of their R&D platform compared to other companies in the segment.
Sales per employee for the market as a whole
ProKidney (PROK) is a late-stage biotech developing a cell therapy for chronic kidney disease. The company is preparing for commercialization but has not yet generated revenue from the product. This chart illustrates its pre-launch readiness: a large team of specialists is focused on R&D and launch preparation, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company ProKidney Corp. (PROK)
ProKidney Corp. is a biotech company developing cell therapies for chronic kidney disease (CKD). It's a huge market, but the challenge is also extremely complex. This chart shows bearish sentiment. Investors are betting that its innovative approach will fail to prove effective in clinical trials and receive regulatory approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ProKidney-Corp.-PROK&v=1772513647689 "Short Shares Chart for the Company ProKidney Corp. (PROK)")
Shares shorted by market segment - Pharma kidney
ProKidney is a biotech company developing a cell therapy (REACT) for chronic kidney disease (CKD). This indicator reflects bearish bets. "Shorts" here are bets that their extremely complex and expensive therapy will not prove effective in clinical trials.
Shares shorted by the overall market
ProKidney is developing a cell therapy for chronic kidney disease. It's a research-stage biotech with no stable revenue. When this chart signals rising fear, investors ruthlessly dump their "money on a dream." PROK's survival depends not on market sentiment, but on the success of its clinical trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ProKidney Corp. (PROK)
ProKidney is a clinical-stage biotech developing cell therapies for kidney disease. The stock is highly speculative. This chart can soar above 70 on positive R&D news. The <30 zone often reflects setbacks, delays, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ProKidney-Corp.-PROK&v=1772513647775 "RSI 14 indicator chart for the company's stock ProKidney Corp. (PROK)")
RSI 14 Market Segment - Pharma kidney
ProKidney (PROK) is a biotech company working on kidney *regeneration*. Their cell therapy (REACT) is designed to "revive" a damaged kidney. The RSI_14_Seg for "Pharma kidney" (biotech) shows the overall sentiment. The chart helps us understand: is PROK's volatility a reflection of their platform or just general hype?
RSI 14 for the overall market
ProKidney (PROK) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PROK (ProKidney Corp.)
ProKidney Corp. (PROK) is a biotech company developing a cell therapy (REACT) for the treatment of chronic kidney disease (CKD) with the goal of preventing dialysis. This chart represents analyst consensus. Their price targets are based on clinical trial data and the huge potential market for CKD patients if the therapy is successful.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PROK-ProKidney-Corp.&v=1772513647877 "A chart showing analyst consensus forecasts for the expected stock price. PROK (ProKidney Corp.)")
The difference between the consensus estimate and the actual stock price PROK (ProKidney Corp.)
ProKidney (PROK) is a biotech company developing a revolutionary cell therapy (REACT), which uses a patient's own cells to repair chronically diseased kidneys. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in this regenerative medicine.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PROK-ProKidney-Corp.&v=1772513647883 "A chart showing the difference between the consensus forecast and the actual stock price. PROK (ProKidney Corp.)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
ProKidney (PROK) is a biopharmaceutical company developing revolutionary cell therapy for chronic kidney disease (CKD) using a patient's own cells. This chart shows general expectations for the kidney pharma sector. It reflects whether experts believe in the potential of "repairing" kidneys instead of dialysis.
Analysts' consensus forecast for the overall market share price
ProKidney (PROK) is a biotech company working on a revolutionary treatment for chronic kidney disease (CKD). They use patient cells to create a living drug that aims to restore kidney function. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough, but extremely expensive, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ProKidney Corp.
ProKidney is a biotech company working on regenerative therapies for chronic kidney disease (CKD). Their approach isn't a cure, but a cell therapy: they take a patient's cells, rejuvenate them, and inject them back into the kidney. This graph is a pure R&D bet. It likely reflects the market's faith in their revolutionary but complex technology and the data from their clinical trials.
AKIMA Market Segment Index - Pharma kidney
ProKidney (PROK) is a clinical-stage biotech and a pioneer in regenerative medicine. The company is developing a revolutionary cell therapy (REACT) that uses a patient's own cells to repair damaged kidneys. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this futuristic (R&D) bet (PROK) differentiate it from the average pharma company?
The AKIM Index for the overall market
ProKidney is a biotech company developing a cell therapy for chronic kidney disease (REACT). The goal is to restore kidney function. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative regenerative approach stacks up against the broader economic trends affecting biotech.
